SeaStar Medical Holding Corporation (ICU)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.46M
Last updated: Nov 17, 2026 at 11:06 AM ET
SeaStar Medical Holding Corporation (ICU) Earnings: Report Dates and Results
SeaStar Medical Holding (ICU) is expected to report earnings on Mar 23, 2027. In the quarter ended Sep 30, 2026, SeaStar Medical Holding reported EPS of -$1.03, below the -$0.95 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ICU has an expected report date of Mar 23, 2027.
ICU Earnings Call
The latest ICU earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 15 quarters below that had an estimate, ICU beat 6, missed 7 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $635000, up 247.0% from $183000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.03 | -$0.95 | -$0.95 - -$0.95 | -8.42% | Miss | N/A | 1 | 0 up, 2 down | Nov 11, 2026 | $635000 |
| Jun 30, 2026 | -$0.91 | -$0.91 | -$1.03 - -$0.91 | 0.00% | In line | N/A | 2 | 0 up, 2 down | Aug 12, 2026 | $615000 |
| Mar 31, 2026 | -$0.90 | -$0.82 | -$0.92 - -$0.73 | -9.76% | Miss | N/A | 2 | 1 up, 0 down | May 13, 2026 | $495000 |
| Dec 31, 2025 | -$0.80 | -$1.02 | -$1.06 - -$0.97 | +21.18% | Beat | N/A | 2 | 1 up, 0 down | Mar 25, 2026 | $420000 |
| Sep 30, 2025 | -$1.30 | -$1.50 | -$1.50 - -$1.50 | +13.33% | Beat | N/A | 1 | 1 up, 0 down | Nov 13, 2025 | $183000 |
| Jun 30, 2025 | -$1.80 | -$4.30 | -$4.30 - -$4.30 | +58.14% | Beat | N/A | 1 | 0 up, 1 down | Aug 13, 2025 | $338000 |
| Mar 31, 2025 | -$4.40 | -$5.20 | N/A | +15.38% | Beat | N/A | N/A | 0 up, 0 down | May 14, 2025 | $293000 |
| Dec 31, 2024 | -$0.90 | -$0.18 | N/A | -400.00% | Miss | N/A | N/A | 0 up, 0 down | Mar 27, 2025 | $67000 |
| Sep 30, 2024 | -$11.00 | -$11.30 | -$11.30 - -$11.30 | +2.65% | Beat | N/A | 1 | 0 up, 0 down | Nov 13, 2024 | $68000 |
| Jun 30, 2024 | -$10.30 | -$14.10 | -$14.10 - -$14.10 | +26.95% | Beat | N/A | 1 | 1 up, 0 down | Aug 13, 2024 | N/A |
| Mar 31, 2024 | -$47.50 | -$37.50 | -$37.50 - -$37.50 | -26.67% | Miss | N/A | 1 | 0 up, 0 down | May 14, 2024 | N/A |
| Dec 31, 2023 | -$0.22 | -$0.13 | -$0.13 - -$0.13 | -69.23% | Miss | N/A | 1 | 0 up, 0 down | Mar 13, 2024 | N/A |
| Sep 30, 2023 | -$92.50 | -$62.50 | -$62.50 - -$62.50 | -48.00% | Miss | N/A | 1 | 0 up, 0 down | Nov 14, 2023 | N/A |
| Jun 30, 2023 | -$62.50 | -$62.50 | -$62.50 - -$62.50 | 0.00% | In line | -446528.6% | 1 | 0 up, 0 down | Aug 14, 2023 | N/A |
| Mar 31, 2023 | -$100.00 | -$50.00 | N/A | -100.00% | Miss | -1000100.0% | N/A | N/A | May 15, 2023 | N/A |
| Dec 31, 2022 | -$2.04 | N/A | N/A | N/A | N/A | -192.3% | N/A | N/A | Mar 30, 2023 | N/A |
| Sep 30, 2022 | -$0.05 | N/A | N/A | N/A | N/A | -350.0% | N/A | N/A | Nov 14, 2022 | N/A |
| Jun 30, 2022 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 16, 2022 | N/A |
| Mar 31, 2022 | $0.01 | N/A | N/A | N/A | N/A | -94.4% | N/A | N/A | Apr 6, 2022 | N/A |
| Dec 31, 2021 | $2.22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2022 | N/A |
| Sep 30, 2021 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 17, 2021 | N/A |
| Jun 30, 2021 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 16, 2021 | N/A |
| Mar 31, 2021 | $0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 24, 2021 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$8.30, after -$69.70 the year before. It was $2.27 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$8.30 | N/A |
| Dec 31, 2024 | -$69.70 | N/A |
| Dec 31, 2023 | -$255.22 | N/A |
| Dec 31, 2022 | -$2.07 | -191.4% |
| Dec 31, 2021 | $2.27 | N/A |
Earnings Calls
The 5 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,800 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,806 | 8 | |
| 2026Q2 | Jun 30, 2026 | 3,812 | 8 | |
| 2026Q1 | Mar 31, 2026 | 4,220 | 8 | |
| 2025Q3 | Sep 30, 2025 | 4,347 | 7 | |
| 2025Q1 | Mar 31, 2025 | 3,965 | 7 |
2026Q3 Earnings Call
Opening remarks
Jackie Cossmon Conference Call Host Thank you, Latif. Good afternoon, and thank you for joining the SeaStar Medical Third Quarter 2026 Financial Results Conference Call. I'm Jackie Cossmon with Wheelhouse Life Science Advisors. Joining me from SeaStar Medical today are Eric Schlorff, Chief Executive Officer; Tim Varacek, Senior Vice President of Commercial and Business Operations; Dr. Kevin Chung, Chief Medical Officer; and Mike Messinger, Chief Financial Officer. I would like to remind listeners that comments made during this call by management will include forward-looking statements within the meaning of federal securities laws. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results. For a list and description of these risks and uncertainties, please review SeaStar Medical's filings with the Securities and Exchange Commission. Furthermore, the content of this conference call contains information that is accurate only as of the date of the live broadcast, November 11, 2026. SeaStar Medical undertakes no obligation to revise or update any statements to reflect events or circumstances, except as required by law. And now I'll turn the call over to Eric. Eric?
Eric Schlorff CEO Thank you, Jackie, and thank you all for joining us today. We made good progress on several fronts this quarter. We saw strong QUELIMMUNE demand in the ultra-rare pediatric AKI market, and we continue to build momentum in educating the critical care pediatric health care community. Kevin Chung, our CMO, presented data on QUELIMMUNE at several medical meetings, and we are already sharing with critical care professionals the statistically significant higher survival in QUELIMMUNE-treated patients in our patient registry that was highlighted at the late-breaking presentation at ASN Kidney Week 2026. Importantly, we believe this growing momentum of interest reinforces the promise of our SCD therapy for our pipeline indications, the first of which is for adult patients with AKI on continuous renal replacement therapy, or CRRT. The NEUTRALIZE-AKI pivotal clinical trial for this patient population is well underway and has enrolled about 75% of its intended 339 patients. The results of this trial will be critical for understanding the role of our SCD therapy in preventing lifelong dialysis treatment and saving lives. As we have said previously, our enrollment in this trial is moderated by strict inclusion and exclusion criteria designed to enroll patients most appropriate for the study, which supports a well-defined trial population and more rigorous evaluation of the SCD's potential benefit in these patients. As a result, we are adjusting our guidance for completion of enrollment in the trial. Based on our current enrollment rate, we would anticipate completing the trial by midyear of 2027.
Frequently Asked Questions About ICU
When is SeaStar Medical Holding's next earnings date?
SeaStar Medical Holding's next earnings report is expected for Mar 23, 2027.
Did ICU beat earnings estimates last quarter?
No. SeaStar Medical Holding reported EPS of -$1.03 for the quarter ended Sep 30, 2026, below the -$0.95 estimate by 8.42%.
What EPS do analysts expect from ICU next quarter?
The consensus EPS estimate for SeaStar Medical Holding for the quarter ending Dec 31, 2026 is -$0.90 from 3 analysts.
How often does ICU beat earnings estimates?
SeaStar Medical Holding beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -38.77%.
ICU pages: Overview, Earnings, Forecast, Financials, Competitors